Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To Carbon Of The Hetero Ring Of The Quinoline Ring System Patents (Class 514/253.08)
-
Patent number: 7691862Abstract: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.Type: GrantFiled: July 2, 2007Date of Patent: April 6, 2010Assignee: Regena Therapeutics LCInventors: Frank Wingrove, Rex McKee
-
Publication number: 20100074942Abstract: Intraocular devices having a drug delivery construct attached thereto, and methods for using the devices for intraocular drug delivery and the treatment and/or prevention of conditions.Type: ApplicationFiled: September 11, 2009Publication date: March 25, 2010Applicant: WASHINGTON, UNIVERSITY OFInventors: Buddy D. Ratner, Tueng T. Shen
-
Publication number: 20100062974Abstract: The invention features a method for treating a subject diagnosed with, or at risk of developing, a bacterial infection by administering to the subject a combination of biologically active agents.Type: ApplicationFiled: April 7, 2009Publication date: March 11, 2010Applicant: Interface Biologics, Inc.Inventors: Frank LaRonde, Hanje Chen, Selva Sinnadurai
-
Patent number: 7671056Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I?): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I?).Type: GrantFiled: June 9, 2006Date of Patent: March 2, 2010Assignee: Wyeth LLCInventors: Magda Asselin, George Theodore Grosu, Annmarie Louise Sabb, Wayne Everett Childers, Lisa Marie Havran, Zhongqi Shen, James Jacob Bicksler, Dan Chaekoo Chong
-
Publication number: 20100035894Abstract: An object is to provide an ophthalmic aqueous preparation excellent in the retention of gatifloxacin in a tear fluid and the preparation of gatifloxacin into an aqueous humor and a conjunctiva. Another object is to prevent the formation of any precipitate and the reduction in viscosity in the aqueous liquid preparation. An aqueous liquid preparation comprising gatifloxacin, a pharmacologically acceptable salt thereof or a hydrate of gatifloxacin or the salt and at least 0.15 w/v % of xanthan gum enables to improve the retention and penetration of gatifloxacin. When at least 0.2 w/v % of sodium chloride is added to the aqueous liquid preparation, the formation of any precipitate and the reduction in viscosity in the aqueous liquid preparation can be prevented.Type: ApplicationFiled: October 11, 2007Publication date: February 11, 2010Inventor: Shirou Sawa
-
Publication number: 20100009979Abstract: The invention relates to the use of quaternary ammonium compounds for preventing precipitations of fluoroquinolones from their solutions and to stable, tolerated pharmaceuticals which are particularly suitable for parenteral use and which contain, in dissolved form, a fluoroquinolone and a quaternary ammonium compound.Type: ApplicationFiled: February 23, 2007Publication date: January 14, 2010Applicant: BAYER ANIMAL HEALTH GMBHInventors: Iris Heep, Kristine Fraatz, Hans-Juergen Hamann, Markus Edingloh
-
Publication number: 20100004189Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator.Type: ApplicationFiled: May 1, 2009Publication date: January 7, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090324709Abstract: The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.Type: ApplicationFiled: September 4, 2009Publication date: December 31, 2009Applicant: Italfarmaco, S.A.Inventors: Jaime Moscoso Del Prado, José Ramón Chantres Antoranz, María Ángeles Elorza Barroeta, Begoña Elorza Barroeta, Manuel Cordoba Diaz
-
Publication number: 20090312279Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.Type: ApplicationFiled: June 22, 2009Publication date: December 17, 2009Applicant: Sterilex Technologies, LLCInventors: Pradip Mookerjee, Shira Kramer, Alexander Josowitz, April Zambelli-Weiner
-
Publication number: 20090306035Abstract: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic formulations comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided.Type: ApplicationFiled: August 25, 2006Publication date: December 10, 2009Applicant: Emory UniversityInventors: Jin Peng, Ge Shan, Stephen Warren
-
Publication number: 20090291964Abstract: The present invention relates to compounds that potentiate the activity of antibacterials. The present invention also relates to compositions useful in treating bacterial infection in mammals, and methods therewith. The present invention also relates to a method of inhibiting bacterial efflux of an antibiotic, thereby increasing the efficacy of the antibiotic.Type: ApplicationFiled: August 3, 2009Publication date: November 26, 2009Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventor: Trudy Hope Grossman
-
Publication number: 20090269396Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: ApplicationFiled: October 30, 2008Publication date: October 29, 2009Inventors: David C. Cipolla, James Blanchard
-
Publication number: 20090270413Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing di-t-butyl phenyl piperazine derivatives of the general formula (1).Type: ApplicationFiled: April 28, 2009Publication date: October 29, 2009Inventors: Robert Galemmo, JR., Gabriel Hum
-
Publication number: 20090247543Abstract: There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin. Further, the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine, methyl parahydroxybenzoate and a salt thereof into the aqueous liquid preparation.Type: ApplicationFiled: March 31, 2009Publication date: October 1, 2009Applicants: Kyorin Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd.Inventor: Shirou SAWA
-
Publication number: 20090238873Abstract: Extended release pharmaceutical formulations are disclosed wherein the formulations contain an extended release portion and an immediate release portion, the extended release portion comprising an active pharmaceutical ingredient and a wax. Methods of making such extended release pharmaceutical formulations are also disclosed.Type: ApplicationFiled: March 18, 2009Publication date: September 24, 2009Applicant: Mylan Pharmaceuticals, Inc.Inventors: Sarat C. Chattaraj, Pavan Bhat, Glenn A. Redelman, David J. Wargo, William Addicks
-
Patent number: 7569563Abstract: The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.Type: GrantFiled: December 28, 2007Date of Patent: August 4, 2009Assignee: AiCuris GmbH & Co. HKInventors: Rudolf Schohe-Loop, Holger Zimmermann, Kerstin Henninger, Dieter Lang, Kai Thede, Chantal Fuerstner, David Brueckner
-
Patent number: 7560483Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.Type: GrantFiled: June 21, 2005Date of Patent: July 14, 2009Assignee: XenoPort, Inc.Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
-
Publication number: 20090163484Abstract: The invention relates to pharmaceutical formulations in liquid form, containing fluoroquinolones and antioxidative sulphur compounds. The formulations are particularly suitable for parenteral uses and are distinguished, inter alia, by good tolerance.Type: ApplicationFiled: February 23, 2007Publication date: June 25, 2009Applicant: BAYER ANIMAL HEALTH GMBHInventors: Iris Heep, Kristine Fraatz, Hans-Jürgen Hamann, Markus Edingloh
-
Patent number: 7538221Abstract: A polymorphic forms of the hydrochloride salt and mesylate salt of racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid, dextrorotatory R-(+)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and S-(?)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid having formula (I) and (II) respectively are described. Processes for their preparation are also described. The invention further relates to methods of using, and pharmaceutical compositions comprising the compounds of the invention for treatment of bacterial infections in mammals.Type: GrantFiled: November 10, 2004Date of Patent: May 26, 2009Assignee: The Company of Wockhardt LimitedInventors: Prasad Keshav Deshpande, Satish Baliram Bhavsar, Yati Chugh, Ravindra Dattatrya Yeole, Noel John De Souza, Mahesh Vithalbhai Patel
-
Publication number: 20090124617Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.Type: ApplicationFiled: December 31, 2008Publication date: May 14, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Susumu WATANUKI, Yuji KOGA, Hiroyuki MORITOMO, Issei TSUKAMOTO, Daisuke KAGA, Takao OKUDA, Fukushi HIRAYAMA, Yumiko MORITANI, Jun TAKASAKI
-
Publication number: 20090124632Abstract: The present invention is generally directed to the treatment of dermatological bacterial infections, burns and wounds. It is more specifically directed to the treatment of such infections, burns and wounds using one or more quinolone antibiotics. In one method of treatment aspect, an aqueous solution containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder. In another method of treatment aspect, an ointment containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder.Type: ApplicationFiled: November 12, 2008Publication date: May 14, 2009Inventor: Reza Babapour
-
Publication number: 20090105272Abstract: The present invention relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.Type: ApplicationFiled: December 21, 2006Publication date: April 23, 2009Inventors: Peter D.J. Grootenhuis, Sara Hadida Ruah, Jinglan Zhou, Ann Hazlewood, Hayley Binch
-
Publication number: 20090088420Abstract: Pharmacophore models to be used in drug design and discovery are provided. An in silico protocol and in vitro assays are presented. Compounds and their pharmaceutically acceptable salts with HIV-1 integrase inhibitory and anti-HIV activity and use thereof in the treatment of HIV/AIDS and related infections either alone or in combination with all the known antiretroviral therapeutics are described.Type: ApplicationFiled: April 14, 2008Publication date: April 2, 2009Applicant: University of Southern CaliforniaInventors: Nouri Neamati, Raveendra S. Dayam
-
Publication number: 20090069339Abstract: The present application describes deuterium-enriched ciprofloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 12, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090054455Abstract: Co-crystals comprising aripiprazole and fumaric acid.Type: ApplicationFiled: February 2, 2007Publication date: February 26, 2009Applicants: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Surya Narayana Devarakonda, Krishnamurthi Vyas, Sivakumar Reddy Bommareddy, Pratap Reddy Padi, Balaji Raghupathy
-
Publication number: 20090053316Abstract: The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention.Type: ApplicationFiled: October 30, 2008Publication date: February 26, 2009Applicant: The University of KansasInventors: Cory J. Berkland, Lianjun Shi
-
Publication number: 20090012072Abstract: The invention relates to pharmaceutical compositions comprising (i) a fluoroquinolone, (ii) a salt formed between a carboxylate anion and a divalent metal cation, (iii) a liquid comprising an organic solvent selected from the group consisting of glycerol, propylene glycol, glycerol formal, and (iv) optionally water. The invention further relates to methods of treating or preventing a condition in an animal comprising administering to the animal in need thereof a pharmaceutical composition of the invention.Type: ApplicationFiled: September 15, 2008Publication date: January 8, 2009Applicant: IDEXX Laboratories, Inc.Inventor: Yerramilli V.S.N. MURTHY
-
Publication number: 20080318918Abstract: Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a nonionic polymer surfactant, such as an alkyl aryl polyether alcohol (e.g., tyloxapol) to the tympanic membrane. The medicaments delivered according to the methods of the invention include antibiotic, antiviral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae.Type: ApplicationFiled: August 25, 2006Publication date: December 25, 2008Inventors: William R. Campbell, Neil E. Paulsen, Roland H. Johnson
-
Publication number: 20080305140Abstract: The present invention provides a method, a kit and compositions for long-term release of a drug at a constant therapeutically effective level for nervous system disorders where adherence to therapeutic regimen is problematic. In particular, to the therapy of psychotic disorders.Type: ApplicationFiled: January 12, 2005Publication date: December 11, 2008Applicant: UNIVERSITY OF PENNSYLVANIAInventors: Steven Siegel, Karen Winey
-
Publication number: 20080280902Abstract: The instant invention provides for compounds which comprise substituted quinolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: January 24, 2006Publication date: November 13, 2008Inventors: Mark E. Fraley, Robert M. Garbaccio, Shaei Y. Huang, Justin T. Steen
-
Publication number: 20080269187Abstract: Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a chemical penetration enhancer, such as propylene glycol. The compositions are applied to the ear so as to contact the outer surface of an intact tympanic membrane to deliver the medicament across the membrane and into the middle ear. The medicaments delivered according to the methods of the invention include antibiotic, anti-viral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae.Type: ApplicationFiled: August 24, 2006Publication date: October 30, 2008Inventors: William R. Campbell, Neil E. Paulsen, Roland H. Johnson
-
Publication number: 20080261964Abstract: The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.Type: ApplicationFiled: December 28, 2007Publication date: October 23, 2008Inventors: Rudolf Schohe-Loop, Holger Zimmermann, Kerstin Henninger, Dieter Lang, Kai Thede, Chantal Fuerstner, David Brueckner
-
Publication number: 20080255125Abstract: The invention relates to pharmaceutical preparations, which are applied to the pelt or skin of animals and are then absorbed by the latter orally.Type: ApplicationFiled: January 7, 2005Publication date: October 16, 2008Applicant: Bayer HealthCare AGInventors: Dirk Mertin, Gerald Beddies, Iris Heep, Nikolaus Kowollik
-
Patent number: 7435737Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: December 7, 2006Date of Patent: October 14, 2008Assignee: Avanir PharmaceutialsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
-
Patent number: 7429580Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: GrantFiled: January 11, 2005Date of Patent: September 30, 2008Assignees: Orexigen Therapeutics, Inc., Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20080139545Abstract: The present invention provides a pharmaceutical composition that includes: (a) at least one of a non-aminoglycoside antibiotic and an anti-inflammatory agent; and (b) a biofilm-dissolving agent.Type: ApplicationFiled: May 22, 2007Publication date: June 12, 2008Inventors: Won-Taek Choe, Joseph Baxter Roberson, Michael T. Murray
-
Publication number: 20080132457Abstract: Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).Type: ApplicationFiled: September 17, 2007Publication date: June 5, 2008Inventors: Keith Bostian, Thomasz Glinka, Olga Lomovskaya, Mark Surber, Neil Berkley, David Griffith
-
Patent number: 7381402Abstract: Aerosol solution formulations for use in an aerosol inhaler which comprise 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]-ethyl]-2(1H)-quinolinone or a salt thereof, in particular the hydrochloride salt (TA 2005), as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid exhibit improved shelf life. The formulation may be optionally contained in a can having part or all of its internal metallic surfaces lined with an inert organic coating.Type: GrantFiled: February 25, 2005Date of Patent: June 3, 2008Assignee: Chiesi Farmaceutici S.p.A.Inventors: David Lewis, David Ganderton, Brian Meakin, Maurizio Delcanale, Fausto Pivetti
-
Patent number: 7320985Abstract: A method for stabilizing an arylcarboxylic acid, which comprises adding a heterocyclic base to the arylcarboxylic acid or a pharmacologically acceptable salt thereof, a stabilizer thereof and an aqueous solution containing a stabilized arylcarboxylic acid. According to the stabilization method of the present invention, arylcarboxylic acid and pharmacologically acceptable salts thereof, particularly pranoprofen, can be stabilized at every temperature range, particularly at lower temperatures, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, ear drop and the like possible.Type: GrantFiled: July 23, 2003Date of Patent: January 22, 2008Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Shirou Sawa
-
Patent number: 7273870Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.Type: GrantFiled: March 3, 2005Date of Patent: September 25, 2007Assignee: WyethInventor: Henderik W. Frijlink
-
Publication number: 20070218038Abstract: Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process.Type: ApplicationFiled: March 15, 2007Publication date: September 20, 2007Applicant: PEGASUS BIOLOGICS, INC.Inventors: Chandrasekaran Nataraj, Gregg Ritter, Thomas Sander
-
Patent number: 7265107Abstract: The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.Type: GrantFiled: March 9, 2005Date of Patent: September 4, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Jing Li, Zhenkun Ma
-
Publication number: 20070202177Abstract: Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.Type: ApplicationFiled: February 27, 2007Publication date: August 30, 2007Applicant: BECTON, DICKINSON AND COMPANYInventor: Minh Quang Hoang
-
Publication number: 20070190109Abstract: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin stearate, ofloxacin palmitate, ofloxacin stearate, moxifloxacin palmitate, moxifloxacin stearate, clindamycin palmitate, and clindamycin stearate. A medical device for implantation, in which the form bodies are arranged on a biodegradable filament at a distance of 1 mm to 25 mm as well as a method for the manufacture of the medical device and the use of the form bodies or the medical device to treat chronic osteomyelitis are described.Type: ApplicationFiled: February 15, 2007Publication date: August 16, 2007Applicant: HERAEUS KULZER GMBHInventors: KLAUS DIETER KUHN, SEBASTIAN VOGT
-
Patent number: 7256187Abstract: The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.Type: GrantFiled: March 9, 2005Date of Patent: August 14, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Jing Li, Charles Z. Ding, Zhenkun Ma
-
Patent number: 7247634Abstract: Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.Type: GrantFiled: January 12, 2005Date of Patent: July 24, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Zhenkun Ma, Yafei Jin, Jing Li, Charles Z. Ding, Keith P. Minor, Jamie C. Longgood, In Ho Kim, Susan Harran, Keith Combrink, Timothy W. Morris
-
Patent number: 7247641Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: August 6, 2002Date of Patent: July 24, 2007Assignee: MGI GP, Inc.Inventors: Weizheng Xu, Dana V. Ferraris, Jia-He Li, Vincent J. Kalish
-
Patent number: 7241746Abstract: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.Type: GrantFiled: August 6, 2003Date of Patent: July 10, 2007Assignee: Regena Therapeutics, LCInventors: Frank Wingrove, Rex McKee
-
Patent number: 7238694Abstract: The present invention relates to rifamycin 3-iminomethylenyl (—CH?N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH?N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.Type: GrantFiled: January 12, 2005Date of Patent: July 3, 2007Assignee: Cumbre Pharmaceuticals, Inc.Inventors: Charles Z. Ding, Yafei Jin, Jamie C. Longgood, Zhenkun Ma, Jing Li, In Ho Kim, Keith P. Minor, Susan Harran
-
Patent number: 7202248Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: January 31, 2006Date of Patent: April 10, 2007Assignee: Avanir PharmaceuticalsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.